Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Farmers Insurance
US Army
Chinese Patent Office
Cerilliant
Healthtrust
Chubb
Merck
Mallinckrodt

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Treatment of human viral infections
Abstract:Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Inventor(s): Rideout; Janet L. (Raleigh, NC), Barry; David W. (Chapel Hill, NC), Lehrman; Sandra N. (Durham, NC), St. Clair; Martha H. (Durham, NC), Furman; Phillip A. (Durham, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/111,205
Patent Claims: 1. A sealed container including a pharmaceutical composition in unit dosage form comprising 5 to 500 mg of 3'-azido-3'-deoxythymidine together with a pharmaceutically acceptable solid carrier.

2. A dose of a pharmaceutical composition comprising 5 to 500 mg of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable liquid carrier.

3. A sealed contaner containing a sterile pharmaceutical composition for parenteral administration including a pharmaceutically acceptable liquid carrier and the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition in unit dosage form comprising per dosage unit 5 to 500 mg of a pharmaceutically acceptable salt of 3'-azido-3'-deoxythymidine together with a pharmaceutically acceptable carrier in solid or liquid form.

5. A pharmaceutical composition in unit dosage form comprising per dosage unit 5 to 500 mg of the 5'-monophosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier in solid or liquid form.

6. A pharmaceutical composition in unit dosage form comprising per dosage unit 5 to 500 mg of the 5'-diphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier in solid or liquid form.

7. A pharmaceutical composition in unit dosage form comprising per dosage unit 5 to 500 mg of the 5'-triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier in solid or liquid form.

8. The composition of claim 2, 4, 5, 6 or 7 in the form of a suspension.

9. The composition of claim 1, 4, 5, 6 or 7 in the form of a suppository.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Moodys
Colorcon
Queensland Health
Harvard Business School
McKesson
Boehringer Ingelheim
US Department of Justice
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot